These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 10621692)

  • 21. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

  • 22. Maximizing exclusivity for drug products.
    French H
    Nat Rev Drug Discov; 2005 Sep; 4(9):709. PubMed ID: 16178117
    [No Abstract]   [Full Text] [Related]  

  • 23. Maintaining patents protecting biologics or small-molecule drugs.
    Marimuthu G; Kumari S; Kandasamy M; Raghunathan S; Saberwal G
    Nat Biotechnol; 2012 Jan; 30(1):50-3. PubMed ID: 22231094
    [No Abstract]   [Full Text] [Related]  

  • 24. Patent reform in the US: what's at stake for pharmaceutical innovation?
    Yancey A; Stewart CN
    Expert Opin Ther Pat; 2010 May; 20(5):603-8. PubMed ID: 20402544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H
    Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
    [No Abstract]   [Full Text] [Related]  

  • 26. Ownership of knowledge--the role of patents in pharmaceutical R&D.
    Correa CM
    Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Replace pharmaceutical patents now.
    Grinols EL; Henderson JW
    Pharmacoeconomics; 2007; 25(5):355-63. PubMed ID: 17488135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Legitimate patent extension or patent system abuse?
    Atkinson JD; Moodie RS
    Pharm Pat Anal; 2013 May; 2(3):317-24. PubMed ID: 24237059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug costs threaten patent protection.
    Cimons M
    Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
    [No Abstract]   [Full Text] [Related]  

  • 30. India remains on US trade "priority watch list" for failing to uphold international drug company patents.
    Arie S
    BMJ; 2013 May; 346():f2949. PubMed ID: 23657189
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmaceuticals, patents, and politics: Canada and Bill C-22.
    Lexchin J
    Int J Health Serv; 1993; 23(1):147-60. PubMed ID: 8425783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL
    Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patent watch.
    Harrison C
    Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274462
    [No Abstract]   [Full Text] [Related]  

  • 34. Patent watch: the patent cliff steepens.
    Harrison C
    Nat Rev Drug Discov; 2011 Jan; 10(1):12-3. PubMed ID: 21193859
    [No Abstract]   [Full Text] [Related]  

  • 35. [From the molecule to the drug: innovation or distribution].
    Ménard HA
    Union Med Can; 1993; 122(1):4. PubMed ID: 8465475
    [No Abstract]   [Full Text] [Related]  

  • 36. Healthcare innovation and patent law's 'pharmaceutical privilege': is there a pharmaceutical privilege? And if so, should we remove it?
    Dutfield G
    Health Econ Policy Law; 2017 Oct; 12(4):453-470. PubMed ID: 28416025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 38. Should the patent system for new medicines be abolished?
    DiMasi JA; Grabowski HG
    Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
    [No Abstract]   [Full Text] [Related]  

  • 39. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV
    Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
    [No Abstract]   [Full Text] [Related]  

  • 40. Compulsory licensing to regulated licensing: effects on the conflict between innovation and access in the pharmaceutical industry.
    Gillat A
    Food Drug Law J; 2003; 58(4):711-40. PubMed ID: 15027457
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.